Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 21:14:1016976.
doi: 10.3389/fphar.2023.1016976. eCollection 2023.

Lung cancer, comorbidities, and medication: the infernal trio

Hélène Pluchart  1   2   3 , Sébastien Chanoine  1   2   4 , Denis Moro-Sibilot  2   4   5 , Christos Chouaid  6   7 , Gil Frey  8 , Julie Villa  9 , Bruno Degano  2   5   10 , Matteo Giaj Levra  4   5 , Pierrick Bedouch  1   2   3 , Anne-Claire Toffart  2   4   5
Affiliations
Review

Lung cancer, comorbidities, and medication: the infernal trio

Hélène Pluchart et al. Front Pharmacol. .

Abstract

Most patients with lung cancer are smokers and are of advanced age. They are therefore at high risk of having age- and lifestyle-related comorbidities. These comorbidities are subject to treatment or even polypharmacy. There is growing evidence of a link between lung cancer, comorbidities and medications. The relationships between these entities are complex. The presence of comorbidities and their treatments influence the time of cancer diagnosis, as well as the diagnostic and treatment strategy. On the other hand, cancer treatment may have an impact on the patient's comorbidities such as renal failure, pneumonitis or endocrinopathies. This review highlights how some comorbidities may have an impact on lung cancer presentation and may require treatment adjustments. Reciprocal influences between the treatment of comorbidities and anticancer therapy will also be discussed.

Keywords: comorbidities; drug-drug interaction; lung cancer; polypharmacy; survival.

PubMed Disclaimer

Conflict of interest statement

HP, SC, PB, GF, JV, and BD have nothing to disclose. A-CT received consulting fees and non-financial support from Astra Zeneca, BMS, MSD, Novartis, Boehringer Ingelheim, Roche, Pfizer. DMS received grants or contracts from any entity from Roche, Astra Zeneca, BMS, Boehringer Ingelheim, Abbvie, Pfizer; received consulting fees from Roche, Astra Zeneca, BMS, MSD, Lilly, Takeda, Boehringer Ingelheim, Abbvie, Becton Dickinson, Pfizer, Novartis; received non-financial support from Roche, Astra Zeneca, BMS, MSD, Lilly, Takeda, Boehringer Ingelheim and Pfizer. CC received grants or contracts from any entity, consulting fees and non-financial support from Astra Zeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Amgen. MGL received grants or contracts from any entity from Astra Zeneca, BMS; received consulting fees from Astra Zeneca, BMS, MSD; received non financial support from MSD, Takeda.

Figures

FIGURE 1
FIGURE 1
Lung, cancer, medication, and comobidities: an infernal trio.
FIGURE 2
FIGURE 2
Consequences of concomitant medications in lung cancer patients.
See this image and copyright information in PMC

References

    1. Aberle D. R., Adams A. M., Berg C. D., Black W. C., Clapp J. D., Fagerstrom R. M., et al. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365 (5), 395–409. 10.1056/NEJMoa1102873 - DOI - PMC - PubMed
    1. Ahn D., Mehta N., Yorio J. T., Xie Y., Yan J., Gerber D. E. (2013). Influence of medical comorbidities on the presentation and outcomes of stage I-iii non–small-cell lung cancer. Clin. Lung Cancer 14 (6), 644–650. 10.1016/j.cllc.2013.06.009 - DOI - PMC - PubMed
    1. Akbulut M., Urun Y. (2020). Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs. Crit. Rev. Oncology/Hematology 145, 102822. 10.1016/j.critrevonc.2019.102822 - DOI - PubMed
    1. Alkan A., Yaşar A., Karcı E., Köksoy E. B., Ürün M., Şenler F. Ç., et al. (2016). Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support. Care Cancer 25, 229–236. 10.1007/s00520-016-3409-6 - DOI - PubMed
    1. Alloubi I., Jougon J., Delcambre F., Baste J. M., Velly J. F. (2010). Early complications after pneumonectomy: Retrospective study of 168 patients. Interact. Cardiovasc. Thorac. Surg. 11 (2), 162–165. 10.1510/icvts.2010.232595 - DOI - PubMed

LinkOut - more resources